Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
XON Intrexon Corporation monthly Stock Chart
XON [NASD]
Intrexon Corporation
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-3.93 Insider Own0.60% Shs Outstand160.77M Perf Week0.43%
Market Cap754.01M Forward P/E- EPS next Y-1.27 Insider Trans352.25% Shs Float135.68M Perf Month6.83%
Income-523.90M PEG- EPS next Q-0.30 Inst Own76.30% Short Float24.81% Perf Quarter-44.69%
Sales144.20M P/S5.23 EPS this Y67.40% Inst Trans2.98% Short Ratio11.27 Perf Half Y-52.19%
Book/sh2.05 P/B2.29 EPS next Y15.60% ROA-64.80% Target Price9.67 Perf Year-69.94%
Cash/sh1.13 P/C4.15 EPS next 5Y39.00% ROE-118.70% 52W Range3.95 - 19.94 Perf YTD-28.29%
Dividend- P/FCF- EPS past 5Y-22.90% ROI-84.20% 52W High-76.48% Beta2.00
Dividend %- Quick Ratio3.60 Sales past 5Y46.50% Gross Margin56.10% 52W Low18.73% ATR0.33
Employees882 Current Ratio3.90 Sales Q/Q-41.30% Oper. Margin- RSI (14)52.67 Volatility5.65% 7.23%
OptionableYes Debt/Eq0.83 EPS Q/Q-10.80% Profit Margin- Rel Volume0.38 Prev Close4.69
ShortableYes LT Debt/Eq0.81 EarningsMay 09 AMC Payout- Avg Volume2.99M Price4.69
Recom3.00 SMA204.34% SMA50-3.64% SMA200-50.12% Volume1,124,026 Change0.00%
Mar-01-19Downgrade Northland Capital Outperform → Market Perform
Jul-17-18Resumed Stifel Buy $72
Jul-16-18Downgrade BofA/Merrill Neutral → Underperform
Nov-10-17Reiterated Stifel Buy $57 → $39
Nov-10-17Reiterated Stifel Buy $39 → $57
Dec-29-16Initiated Northland Capital Outperform $40
May-03-16Initiated JMP Securities Mkt Outperform
Mar-01-16Reiterated Stifel Buy $69 → $57
Mar-01-16Reiterated Mizuho Neutral $28 → $29
Jan-25-16Reiterated Mizuho Neutral $42 → $28
Nov-11-15Upgrade Mizuho Underperform → Neutral $45 → $42
Oct-19-15Reiterated Wunderlich Buy $70 → $50
Oct-14-15Initiated BofA/Merrill Neutral $35
Sep-21-15Initiated Stifel Buy $69
Aug-11-15Downgrade Mizuho Neutral → Underperform $45
Aug-11-15Downgrade JP Morgan Overweight → Neutral
Jul-27-15Reiterated Wunderlich Buy $55 → $70
Jun-09-15Initiated Wunderlich Buy $55
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-03-15Reiterated Mizuho Buy $32 → $50
May-24-19 09:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $1.9 million of Shares GuruFocus.com
May-21-19 11:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.9 million of Shares GuruFocus.com
11:41AM  Weekly CEO Buys Highlight GuruFocus.com
May-20-19 07:22PM  Cramer's lightning round: I feel bad if you own Intrexon It's a loser CNBC
02:55PM  Intrexon CEO buys up more company shares American City Business Journals
May-15-19 08:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $5.5 million of Shares GuruFocus.com +6.29%
May-13-19 07:30AM  Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire
May-10-19 08:34AM  Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues Zacks
May-09-19 04:10PM  Intrexon Reports First Quarter 2019 Financial Results PR Newswire
May-02-19 04:30PM  AquaBounty Technologies, Inc. Announces Results for the Quarter Ended March 31, 2019, and Company Update GlobeNewswire
04:05PM  Intrexon to Release First Quarter 2019 Financial Results on May 9th PR Newswire
01:53PM  Heres What Hedge Funds Think Of Intrexon Corp (XON) Insider Monkey
10:32AM  Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-29-19 07:30AM  Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting PR Newswire
Apr-25-19 04:05PM  Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland PR Newswire
Apr-17-19 04:45PM  AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares GlobeNewswire -12.43%
Apr-16-19 10:59AM  Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises Zacks +6.51%
07:30AM  Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper PR Newswire
Apr-15-19 06:30AM  Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy GlobeNewswire
Apr-10-19 07:30AM  Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference PR Newswire
Apr-09-19 04:00PM  AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire -5.94%
07:30AM  Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development PR Newswire
Apr-08-19 08:28AM  Why Intrexon Stock Dropped 34% in March Motley Fool
Apr-04-19 09:55PM  AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock GlobeNewswire
04:08PM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-03-19 07:30AM  Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management PR Newswire
Apr-02-19 07:00AM  AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire
Mar-30-19 09:30AM  Why Is Intrexon (XON) Down 34% Since Last Earnings Report? Zacks
Mar-22-19 04:00AM  Next Green Wave's Nursery Botticelli(TM) Research & Development Program Begins Newsfile -6.77%
Mar-21-19 04:01PM  AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire +5.69%
Mar-19-19 06:00AM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-18-19 04:00PM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-12-19 07:20AM  Jim Cramer Shares His Thoughts On Ambarella, Centurylink, Chipotle And More Benzinga
Mar-08-19 03:19PM  AquaBounty Technologies, Inc. - FDA Lifts Import Alert on AquAdvantage Salmon GlobeNewswire
Mar-07-19 05:00PM  AquaBounty Technologies, Inc. Results for the year ended December 31, 2018 GlobeNewswire +9.11%
Mar-05-19 06:41PM  Edited Transcript of XON earnings conference call or presentation 28-Feb-19 10:30pm GMT Thomson Reuters StreetEvents +21.26%
04:01PM  Here's What Caused Intrexon's 21% Rally Today Motley Fool
07:45AM  Market Trends Toward New Normal in Ritchie Bros. Auctioneers, Empire State Realty Trust, Synergy Resources, IQVIA, Intrexon, and Denbury Resources Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-04-19 04:47PM  Here's Why Intrexon Crashed (Again) Today Motley Fool -18.18%
04:03PM  Intrexon, Surterra Wellness Collaborate On Plant Propagation For Cannabis Cultivation Benzinga
07:30AM  Intrexon and Surterra Wellness to Collaborate on Botticelli Next Generation Plant Propagation for Cannabis Cultivation PR Newswire
Mar-01-19 09:16AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks -36.51%
01:40AM  Intrexon Corp (XON) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:15PM  Intrexon Reports 2018 Fourth Quarter and Year End Financial Results PR Newswire
Feb-27-19 07:30AM  Intrexon to Showcase Differentiated Methane Bioconversion Platform at Upcoming Petroleum Industry Events PR Newswire
Feb-21-19 07:30AM  Intrexon to Announce Fourth Quarter 2018 Financial Results on February 28th PR Newswire
Feb-20-19 09:00AM  Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference PR Newswire
Feb-14-19 08:20AM  Consolidated Research: 2019 Summary Expectations for Sabre, Groupon, Intrexon, Comfort Systems, O'Reilly Automotive, and Ellington Financial Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-11-19 07:30AM  Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients PR Newswire
Jan-25-19 09:44AM  Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds Zacks
Jan-21-19 09:21AM  Can This Stock Go From Potential Zika Virus Savior to Marijuana Kingpin? Motley Fool
Jan-16-19 04:19PM  Intrexon Signs Licensing Agreement with Next Green Wave Zacks
Jan-15-19 11:22AM  RETRANSMISSION: Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon Newsfile
07:30AM  Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon Newsfile
07:30AM  Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli Next Generation Plant Propagation Platform into Development for Cannabis PR Newswire
Jan-08-19 08:00AM  Investing in a New Age of Cannabinoid Production for Cost Efficiency and Scalability GlobeNewswire
Jan-02-19 07:30AM  Intrexon Announces Presentations at Upcoming Investor Conferences PR Newswire +9.33%
Dec-31-18 07:30AM  Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-24-18 07:30AM  Precigen to Host Conference Call to Provide Business Updates PR Newswire
Dec-21-18 12:35PM  Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS) PR Newswire
07:30AM  Exemplar Genetics and Mayo Clinic Launch Joint Venture Focused on Development of Human Liver Cells to Advance Medical Research PR Newswire
Dec-20-18 03:23PM  AquaBounty Technologies, Inc.: Issuance of USDA labeling rule GlobeNewswire
07:42AM  Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon PR Newswire
07:30AM  Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program PR Newswire
Dec-18-18 07:30AM  Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production PR Newswire -6.65%
Dec-14-18 08:41AM  Do Options Traders Know Something About Intrexon (XON) Stock We Don't? Zacks
Dec-08-18 09:30AM  Why Is Intrexon (XON) Down 31.5% Since Last Earnings Report? Zacks
Nov-30-18 07:35AM  New Research: Key Drivers of Growth for Intrexon, Graham, The Walt Disney, Toyota Motor, Atlas Air Worldwide, and SITO Mobile Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-29-18 02:31PM  Oil recovers after dropping below $50 Yahoo Finance Video
Nov-28-18 07:30AM  Oxitec Transitioning Friendly Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs PR Newswire +6.70%
07:30AM  AquaBounty appoints Sylvia Wulf as Chief Executive Officer GlobeNewswire
Nov-21-18 01:42PM  Not business as usual: Rockville biotechs new CEO wants to turn things around American City Business Journals
Nov-09-18 02:08PM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3 Zacks -18.53%
07:00AM  Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Intrexon ACCESSWIRE
Nov-08-18 11:16PM  Edited Transcript of XON earnings conference call or presentation 8-Nov-18 10:30pm GMT Thomson Reuters StreetEvents
04:10PM  Intrexon Announces Third Quarter 2018 Financial Results PR Newswire
07:56AM  A Preview Of Intrexon's Q3 Earnings Benzinga
Nov-02-18 07:30AM  AquaBounty Technologies, Inc. Results for the quarter and nine months ended September 30, 2018 GlobeNewswire
Nov-01-18 03:37PM  Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp. PR Newswire +9.69%
07:30AM  Intrexon to Announce Third Quarter 2018 Financial Results on November 8th PR Newswire
Oct-29-18 05:14PM  Bragar Eagel & Squire, P.C. is Investigating Intrexon Corporation (XON) on Behalf of Stockholders and Encourages XON Investors to Contact the Firm GlobeNewswire
07:30AM  ActoBio Therapeutics Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes PR Newswire
Oct-25-18 06:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
10:43AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON) ACCESSWIRE
Oct-24-18 07:30AM  Intrexon Announces the Formation of Bioinformatics Hub in Munich PR Newswire -15.37%
Oct-23-18 03:05PM  Gaithersburg biotech CEO to step down American City Business Journals
08:40AM  Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-18-18 08:43AM  Oxitec to Develop 2nd Friendly Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes PR Newswire
Oct-16-18 05:28PM  AquaBounty receives construction loan to support development efforts at its Rollo Bay property GlobeNewswire +5.06%
04:56PM  INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders GlobeNewswire
Oct-12-18 07:38PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON GlobeNewswire
Oct-09-18 07:00AM  Ziopharm and Precigen Redefine Relationships, Announce New License Agreement GlobeNewswire
Oct-03-18 09:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
Sep-26-18 07:52PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE
Sep-25-18 03:00PM  Intrexons Latest Pitch: Were a Pot Stock Motley Fool -9.33%
08:45AM  Implied Volatility Surging for Intrexon (XON) Stock Options Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Intrexon and Tilray ACCESSWIRE
07:30AM  Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-24-18 05:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE +31.52%
01:31PM  Merger Mania: Examining the Latest M&A News & Trends | Free Lunch Zacks
Intrexon Corporation engage in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRK RANDAL JChief Executive OfficerMay 24Buy4.6872,430338,972985,177May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 24Buy4.68108,645508,45917,534,241May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 23Buy4.67128,626600,68317,470,818May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 23Buy4.6785,750400,453970,691May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 22Buy4.70115,187541,379953,541May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 22Buy4.70172,779812,06117,395,730May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 21Buy4.7490,335428,18817,294,866May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 21Buy4.7460,223285,457930,504May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 20Buy4.63301,6701,396,732918,459May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 20Buy4.63452,5022,095,08417,242,131May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 17Buy4.6990,794425,82416,977,975May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 17Buy4.6960,530283,886858,125May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 15Buy4.59314,0501,441,490846,019May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 15Buy4.59471,0772,162,24316,924,973May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 14Buy4.37221,251966,86716,649,972May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 14Buy4.37147,500644,575783,209May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 13Buy4.25376,9321,601,961753,709May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 13Buy4.25565,3992,402,94616,520,814May 15 05:36 PM
KIRK RANDAL J10% OwnerApr 03Sale0.6595,24161,90762,342Apr 03 05:13 PM
KIRK RANDAL J10% OwnerApr 02Sale0.6613,6469,00688,422Apr 03 05:13 PM
KIRK RANDAL J10% OwnerApr 01Sale0.6741,67827,92492,159Apr 03 05:13 PM
MITCHELL DEAN JDirectorMar 12Option Exercise3.178,90628,23241,750Mar 12 07:11 PM
Reed Thomas D.Chief Science OfficerMar 05Sale4.662,30010,71841,705Mar 06 09:07 PM
Reed Thomas D.Chief Science OfficerMar 04Sale4.18225,500943,69044,005Mar 06 09:07 PM
ALVAREZ CESAR LDirectorFeb 19Option Exercise3.172,9689,409117,817Feb 21 04:46 PM
Frank StevenDirectorFeb 12Option Exercise3.172,9689,409195,225Feb 14 04:41 PM
Reed Thomas D.Chief Science OfficerFeb 07Option Exercise3.172,9699,41296,280Feb 11 04:57 PM
LIFFMAN JOEL DSVP, FinanceJan 04Sale7.033,72526,18785,541Jan 04 06:46 PM
Reed Thomas D.Chief Science OfficerJan 03Sale7.072,94420,81679,537Jan 04 06:47 PM
Perez Jeffrey ThomasSVP, IP AffairsJan 03Sale7.073,51424,84618,789Jan 04 06:48 PM
Lehr Donald P.Chief Legal OfficerJan 03Sale7.073,83227,09434,183Jan 04 06:48 PM
Sterling Rick L.Chief Financial OfficerJan 03Sale7.073,51424,84680,873Jan 04 06:46 PM
Sabzevari HelenPresident, Precigen, Inc.Jan 03Sale7.073,83227,09422,532Jan 04 06:46 PM
Nimrodi NirChief Business OfficerJan 03Sale7.074,05828,6925,708Jan 04 06:45 PM
Walsh Robert F. IIISVP, Energy & Fine Chem.Jan 03Sale7.074,05828,6925,708Jan 04 06:46 PM
Reed Thomas D.Chief Science OfficerDec 31Sale6.3630,000190,67172,715Jan 03 05:56 PM
LIFFMAN JOEL DSVP, FinanceOct 15Sale14.5979,0001,152,80879,500Oct 17 07:51 PM
Sabzevari HelenPresident, Precigen, Inc.Jul 18Sale14.548,402122,16516,598Jul 19 06:03 PM
KIRK RANDAL JChief Executive OfficerJul 03Buy13.377,479,43199,999,99215,937,319Jul 06 04:46 PM
open in yahoo | open in reuters | open in google